IO-202
Based on 1 Customer Validation
IO-202 is a high-affinity LILRB4/ILT3 binder and myeloid checkpoint inhibitor. IO-202 blocks APOE binding and LILRB4 activation to reverse T-cell suppression and enhance T-cell cytotoxicity, while eliminating LILRB4-high-expressing leukemic blasts via ADCC and ADCP mechanisms. IO-202 promotes dendritic cell maturation and antigen presentation, reshapes the phenotype of tumor-associated macrophages, and reduces myeloid-derived suppressor cells. IO-202 is widely applicable to research on relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and solid tumors.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 99.43%
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
Isotype
Human IgG4 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
LILRB4 |
In Vitro
IO-202 reverses AML cell-mediated T-cell suppression and activates T-cell cytotoxicity against leukemic cells in vitro via high-affinity binding to human LILRB4 and blockade of APOE-mediated LILRB4 activation[1].
IO-202 (15 μg/mL; 2 days) enhances DC activation (increased CD86 and HLA-DR expression) and reduces a tolerogenic phenotype (decreased CD209 expression) when used to treat healthy human donor monocyte-derived dendritic cells during LPS stimulation[3].
IO-202 (15 μg/mL; 2 days during Mo-DC culture, 4 days during T cell co-culture) enhances DC activation marker expression, IL-12 production, and T cell-derived IFNγ production when used to treat human monocyte-derived dendritic cells during CD40L-induced maturation/activation and subsequent allogeneic T cell co-culture, but has no effect on immature Mo-DCs[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human monocyte-derived dendritic cells
-
Concentration:15 μg/mL
-
Incubation Time:2 days during Mo-DC culture, 4 days during T cell co-culture
-
Result:Enhanced DC activation marker expression, IL-12 production, and T cell-derived IFNγ production.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cx3cr1-Cre/Rosa26-LILRB4 transgenic[3]
-
Dosage:10 mg/kg
-
Administration:administered on day 10 and day 20 post tumor implant
-
Result:Achieved significant tumor growth inhibition with mean tumor volume at day 27 post tumor implant being substantially lower.
Reduced the frequencies of myeloid-derived suppressor cells (including PMN-MDSCs) among tumor-infiltrating leukocytes.
Increased the frequencies of conventional CD4+ T cells and NKT cells among tumor-infiltrating leukocytes.
Decreased the expression of the anti-inflammatory marker CD206 on tumor-associated macrophages (TAMs).
Increased MHCII expression on TAMs.
Gene ID
Accession
Target
LILRB4/ILT3/CD85k
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Anwendung
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
Color Colorless to light yellow
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)